What: Ionis Pharmaceuticals (NASDAQ: IONS) is down nearly 40% at 1:15 p.m. EDT after the company announced that its partner, GlaxoSmithKline (NYSE: GSK), doesn’t plan to initiate a phase 3 for IONIS-TTRRx in patients with transthyretin (TTR)-related amyloid cardiomyopathy.
Yet.